CNS & Neurological Disorders - Drug Targets
Title:Commentary: Endophenotypes as Disease Modifiers: Decoding the Biology of Alzheimer’s by Genome-wide Association Studies
Volume: 17 Issue: 1
Author(s): A.R. Neelakandan and G.K. Rajanikant*
Affiliation:
- School of Biotechnology, National Institute of Technology Calicut, Calicut-673601,India
Export Options
About this article
Cite this article as:
Neelakandan A.R. and Rajanikant G.K.*, Commentary: Endophenotypes as Disease Modifiers: Decoding the Biology of Alzheimer’s by Genome-wide Association Studies, CNS & Neurological Disorders - Drug Targets 2018; 17 (1) . https://dx.doi.org/10.2174/1871527317666180213143832
DOI https://dx.doi.org/10.2174/1871527317666180213143832 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Endothelial Growth Factor (VEGF) Induced Proliferation of Human Fetal Derived Ciliary Epithelium Stem Cells is Mediated by Jagged - N Cadherin Pathway
Current Neurovascular Research Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease
Current Alzheimer Research Conference Report:
CNS & Neurological Disorders - Drug Targets Flavonoids and its Neuroprotective Effects on Brain Ischemia and Neurodegenerative Diseases
Current Drug Targets Genetics of Ion Channels in Sudden Unexplained Death Syndrome: Moving Beyond Idiopathic Reactions To Personalized Risk Assessment
Current Pharmacogenomics and Personalized Medicine Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Application of Vibrational Spectroscopy to Study Solid-state Transformations of Pharmaceuticals
Current Pharmaceutical Design ADAM-Integrin Interactions: Potential Integrin Regulated Ectodomain Shedding Activity
Current Pharmaceutical Design Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care
Current Neuropharmacology Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques
Neuroscience and Biomedical Engineering (Discontinued) Galantamine-based Hybrid Molecules with Acetylcholinesterase, Butyrylcholinesterase and γ-Secretase Inhibition Activities
Current Alzheimer Research Editorial (Thematic Selection: 'Glutamatergic-based Rapid Acting Antidepressants: The Link to Synaptic Plasticity')
Current Neuropharmacology Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease
Current Drug Targets Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Current Drug Targets - Inflammation & Allergy FMRI and Multiple Sclerosis
Current Medical Imaging Understanding Non-Mendelian Genetic Risk
Current Genomics Pharmacogenetics of Bipolar Disorder
Current Pharmacogenomics L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) β-Amyloid Fibrillation and/or Hyperhomocysteinemia Modify Striatal Patterns of Hyaluronic Acid and Dermatan Sulfate: Possible Role in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research